Cancer Targeted Technology (CTT), a Seattle-based biotechnology company, has been awarded a Fast Track Small Business Innovation Research (SBIR) grant totaling $2.4 million from the National Cancer Institute (NCI). The funds will support the development of CTT2274, an innovative Prostate-Specific Membrane Antigen (PSMA)-targeted small molecule drug conjugate designed for the treatment of metastatic prostate cancer.
CTT2274 is a prodrug engineered to selectively target and bind to PSMA, a protein overexpressed on prostate cancer cells, particularly in metastatic and castration-resistant disease. The unique phosphoramidate-based agents bind irreversibly to PSMA, enhancing uptake and internalization by tumor cells, leading to increased accumulation of the therapeutic payload. Once inside the cancer cell, CTT2274 releases MMAE, a potent cytotoxic agent, directly within the tumor, minimizing systemic exposure and potential side effects.
Preclinical Efficacy and Safety
Preclinical studies evaluating CTT2274 in mice bearing human prostate tumors have demonstrated promising results, including tumor remission and an overall increase in survival. Notably, the drug exhibited excellent safety at doses effective in inhibiting or reversing tumor growth, attributed to the localized release of MMAE within the tumor cells.
Development Plan and Future Clinical Trials
The Phase I portion of the grant, valued at $400,000 and expected to be completed in Q2 2025, will focus on additional non-clinical efficacy studies and manufacturing optimization. Phase II will involve further manufacturing and safety assessments necessary to support an Investigational New Drug (IND) application, targeted for completion in Q2 2026. CTT anticipates initiating clinical trials with CTT2274 in metastatic prostate cancer patients in 2026.
Expert Commentary
"CTT2274 has a unique structure and linker that maximizes tumor uptake and allows for release of the chemotherapeutic drug only within the tumor cell thus minimizing potential side effects from the chemotherapy. No other prodrug like this is being developed for prostate cancer and CTT2274 holds great promise as a future treatment for men suffering from prostate cancer," stated Dr. Beatrice Langton-Webster, CEO of CTT and Principal Investigator on the grant.
